The Food and Drug Administration yesterday approved its first “biosimilar” drug — a lower-cost version of an expensive, complex medication — which could boost market competition and lead to billions of dollars in savings for insurers and patients. Aaron Kesselheim, associate professor of medicine at Brigham and Women’s Hospital, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?